Enilloring (Etonogestrel/Ethinyl Estradiol) Patent Expiration, LOE Window & CMS Spending

Enilloring (Etonogestrel/Ethinyl Estradiol) by Xiromed: Off-Patent Genericized (AB Competition), 4 AB generics, $4.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorXiromed
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$4.0M
2024 Medicare Part D Spend$194K
2024 Medicaid Spend$3.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel